Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma

British Journal of Surgery

Volumn 94, Issue 10, 2007, Pages 1293-1299

  Van Akkooi, A C J ^a   Bouwhuis, M G ^a   De Wilt, J H W ^a   Kliffen, M ^a   Schmitz, P I M ^a   Eggermont, A M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 35348862360     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5814     Document Type: Article

References (26)

1. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977; 297: 627-630.
2. Sim FH, Taylor WF, Ivins JC, Pritchard DJ, Soule EH. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer 1978; 41: 948-956.
3. Hochwald SN, Coit DG. Role of elective lymph node dissection in melanoma. Semin Surg Oncol 1998; 14: 276-282.
4. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998; 351: 793-796.
5. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.
6. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N et al. Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
7. van Akkooi AC, de Wilt JH, Verhoef C, Graveland WJ, van Geel AN, Kliffen M et al. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer 2006; 42: 372-380.
8. Vuylsteke RJ, van Leeuwen PA, Statius Muller MG, Gietema HA, Kragt DR, Meijer S. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 2003; 21: 1057-1065.
9. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976-983.
10. van Akkooi AC, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, Eggermont AM et al. Clinical relevance of melanoma micrometastases (< 0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 2006; 17: 1578-1585.
11. van Akkooi AC, Bouwhuis MG, van Geel AN, Hoedemaker R, Verhoef C, Grunhagen DJ et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol 2007; 33: 102-108.
12. Statius Muller MG, Borgstein PJ, Pijpers R, van Leeuwen PA, van Diest PJ, Gupta A et al. Reliability of the sentinel node procedure in melanoma patients: analysis of failures after long-term follow-up. Ann Surg Oncol 2000; 7: 461-468.
13. Cook MG, Green MA, Anderson B, Eggermont AM, Ruiter DJ, Spatz A et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 2003; 200: 314-319.
14. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2 b versus observation in patients with stage IIb/III melanoma (EORTC 18 952): randomised controlled trial. Lancet 2005; 366: 1189-1196.
15. Eggermont AM, Keilholz U, Testori A, Cook M, Lienard D, Ruiter DJ. The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer. Ann Surg Oncol 2001; 8(Suppl): 38S-40S.
16. Cascinelli N, Bombardieri E, Bufalino R, Camerini T, Carbone A, Clemente C et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol 2006; 24: 4464-4471.
17. Morton DL, Hoon DS, Cochran AJ, Turner RR, Essner R, Takeuchi H et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003; 238: 538-550.
18. Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7: 87-97.
19. Essner R, Conforti A, Kelley MC, Wanek L, Stern S, Glass E et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 1999; 6: 442-449.
20. Doubrovsky A, De Wilt JH, Scolyer RA, McCarthy WH, Thompson JF. Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma. Ann Surg Oncol 2004; 11: 829-836.
21. Kretschmer L, Hilgers R, Mohrle M, Balda BR, Breuninger H, Konz B et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer 2004; 40: 212-218.
22. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-1317.
23. Thomas JM. Time for comprehensive reporting of MSLT-I. Lancet Oncol 2006; 7: 9-11.
24. Thomas JM. Caution with sentinel node biopsy in cutaneous melanoma. Br J Surg 2006; 93: 129-130.
25. Andtbacka RH, Gershenwald JE, Prieto VG, Johnson M, Diwan H, Lee JE et al. Microscopic tumor burden in sentinel lymph nodes (SLNs) best predicts nonsentinel lymph node (NSLN) involvement in patients with melanoma. J Clin Oncol 2006; 24(Suppl 18S): 8004 (Abstract).
26. Hermanek P, Hutter RV, Sobin LH, Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 1999; 86: 2668-2673.